RENALYTIX PLC (RENX) — Investment Research Note

Executive summary

Renalytix is a loss-making UK-listed precision-diagnostics company selling KidneyIntelX.dkd, an FDA-approved, Medicare-reimbursed ($950/test) prognostic blood test for early-stage diabetic kidney disease, commercialised largely in the US. Across the covered period the operating trajectory has been persistent losses, revenue running years behind original ambitions, and repeated equity raises: HY26 revenue was only $1.6m against $7.9m of admin costs, and management cut FY26 revenue guidance from $8.4m to c.$4m between Sept 2025 and Feb 2026 2025-09-23 & 2026-02-11. The single most important valuation point today is that the company is sub-scale, cash-burning (~$12m/yr), with a going-concern material uncertainty flagged in its own accounts and a shareholder circular for a further fundraise dated September 2026 2026-03-26 HY & 2026-09-08.

Fair value estimate

• Methodology: EV/forward-sales cross-check + discounted probability-weighted scenarios. DCF is inappropriate given the company is unprofitable, cash-negative, and has a track record of large downward revisions.
• Assumptions:
  • FY26 revenue: c.$4m (management guidance) → ~£3m at $1.27/£.
  • FY27 revenue: I discount management's aspirational $19m (Sept-25) by ~60% given the same source's FY26 miss; central FY27 estimate $7–10m.
  • Multiple: 3–6x forward sales — a reasonable range for a small, loss-making US diagnostics peer with reimbursement in place but weak execution.
  • Dilution overhang: 603.8m shares outstanding today vs. 74m only three years ago; convertible bond still has ~$3.8m host contract + $0.5m derivative; a further placing is being voted on 28 Sept 2026 2026-09-08.
• Fair-value range: 3p – 7p per share, implied market cap £18m – £42m (midpoint ~£30m / 5p).
• Vs. current mcap £37.1m (6.15p): midpoint downside ~ –19%; range covers roughly –51% to +14%. View: fair-to-modestly overvalued after the recent 3–4x rally off the April lows.

Sector context

• ICB classification (Health Care) is correct; sub-sector is Medical Equipment & Services / In-vitro Diagnostics.
• Quality/growth/leverage profile is well below typical listed diagnostics peers: sub-scale revenue, negative equity ($1.2m deficit at Dec-25), material going-concern uncertainty, and repeated dilutive fundraises.
• Comparable listed peers (loosely): Verici Dx (VRCI, spun out of RENX), EKF Diagnostics (EKF), Genedrive (GDR). None are directly comparable — RENX sits at the pre-scale, pre-profitability end.

Investment thesis (3 bullets)

1. Regulatory & reimbursement moat is genuine: kidneyintelX.dkd is the only FDA-authorised, Medicare-reimbursed prognostic test at $950/reportable result, with KDIGO guideline recognition 2026-03-26 HY. That is a hard-won and defensible position that a competitor cannot replicate quickly.
2. Recent commercial re-platforming towards EHR integrations (5 fully integrated systems, 8 more in progress, ~10,000 eligible patients being onboarded) and a stated Tempus AI collaboration could plausibly re-accelerate volumes in H2 FY26 / FY27 2026-02-11 & 2026-03-26 HY.
3. Very low base-effect optionality: if a large-scale distribution partnership (management flagged discussions with major US diagnostic/lab companies in the FY26 half-year) is signed, revenues can multiply from a tiny base with limited incremental sales-force spend 2026-03-26 HY.

Key risks (3 bullets)

1. Going-concern uncertainty is disclosed by the directors themselves: HY26 accounts state a "material uncertainty which may cast significant doubt on the Group's ability to continue as a going concern" 2026-03-26 HY. Cash was $3.4m at the release date against ~$6m half-year burn.
2. Serial guidance misses and heavy dilution: FY26 was guided at $8.4m in Sept-25 and cut to $4m by Feb-26; FY27 was $17.5m in Mar-25 and $19m in Sept-25 — none of these numbers is credible without new evidence. Share count has grown from ~74m (2022) to 603.8m (Sept-26), i.e. ~8x dilution 2025-09-23, 2026-02-11, 2024-03-12.
3. Concentration and execution risk on EHR/large-partner strategy: management explicitly says implementation cycles at large multi-site organisations extend beyond initial projections 2026-03-26 HY. Failure to sign a national distribution deal in CY2026 would force further dilutive equity raises.

Operating leverage

On paper the leverage story is attractive: gross margin was 50% in HY26 ($0.8m COGS on $1.6m revenue) and admin costs of $7.9m are almost entirely fixed (employees $4.4m, IT $0.5m, listing/insurance $0.3m, stock-based comp $0.6m) 2026-03-26 HY. Management explicitly says the new laboratory facility is designed to "reduce fixed costs per test as utilisation scales" and "enhance long-term operating leverage" 2026-03-26 HY. In theory a 10-fold revenue jump from $1.6m/half to $15–20m/half would push contribution from ~$0.8m to $8–10m, taking the business through breakeven without linearly scaling admin. In practice this leverage is only unlocked by material revenue growth that has not materialised across the period covered: revenue in HY26 was $1.6m, essentially flat with HY25 ($1.3m) and 4-5 years behind management's original launch trajectory. The operating leverage is real but latent, and the base is so small that fixed-cost coverage is the real problem, not incremental margin.

Value-trap signals

• Repeated equity raises at declining prices: 20p (Mar-24), 9p (Sept-24), 9.5p (Sept-25) with each round oversubscribed only because prior cash was near-exhausted.
• Chronic guidance misses: FY26 revenue cut from $8.4m to $4m within 5 months.
• Massive dilution: 8x share-count growth in ~3 years without commensurate revenue traction.
• Convertible bondholder repeatedly restructured rather than paid in cash.
• Going-concern material uncertainty disclosed by auditors' equivalent basis.
• Delisted from Nasdaq and moved to OTCQB in Oct-24 to cut costs 2024-09-30.
• Founder/related-party dependency: Mount Sinai still holds ~11% and is co-founder — heavy licence and royalty obligations to them.
• These are classic value-trap markers, not merely temporary mispricing.

Earnings vs. expectations

Across the covered filings, RENX has systematically missed its own targets. In Oct-2024 the placing prospectus targeted $3.2m FY25 / $8.5m FY26 / $17.5m FY27 2024-09-30; a Sept-25 update raised FY26 to $8.4m and FY27 to $19m 2025-09-23; in Feb-26 the H1 trading update cut FY26 to $4m 2026-02-11. FY25 delivered $3.0m (roughly in line with the reduced $3.2m). Q3 FY25 delivered "20% qoq growth" and 1,000 billable tests, which was in line — but subsequent aspirational targets ($42m FY28) were never remotely on trajectory. Pattern: short-term guidance broadly met; medium-term ambitions repeatedly slashed.

Conviction

3 — moderate. The fair-value call is anchored by three well-disclosed facts: (i) HY26 actuals, (ii) a stated $4m FY26 guide, and (iii) a going-concern disclosure. It is limited by (a) genuine uncertainty over whether a large distribution partnership is signed in CY2026 (which would materially reshape the fair value), and (b) the very small revenue base making any multiple-based valuation highly sensitive to the input growth assumption.

Driver scoring rationale

• AI beneficiary (25): RENX brands itself "AI-enabled" but is a diagnostics test that uses ML in its algorithm — it is not a recipient of AI capex. Its addressable market does not expand as agentic AI is adopted. Press-release AI language, not real AI-receiver economics.
• Operating leverage (65): high fixed cost base, ~50% gross margin, latent leverage — but only meaningful if revenue scales, which is uncertain.
• Earnings surprise trend (25): repeated guidance cuts (FY26 halved within 5 months); pattern of missed medium-term targets.
• Cyclicality (20): healthcare diagnostics is largely non-cyclical.
• Moat (55): FDA authorisation + Medicare reimbursement + KDIGO guideline inclusion is a genuine but narrow moat; competitors are catching up and the moat has not yet translated into commercial scale.
• Leverage (60): negative equity, going-concern uncertainty, dependent on serial equity raises — treat as high financial risk.
• Earnings quality (30): recurring restatements around convertible fair-value adjustments; loss-making with no cash conversion; going-concern warning.
• Management quality (30): repeated guidance misses, chronic dilution, cost-cut execution has been improving, but capital allocation track record is poor.
• Growth momentum (35): revenue grew 23% h/h (HY26 vs HY25) but from a very small base and against much higher guided targets; direction positive, velocity poor.